These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 29183206)

  • 1. Fibrates in the management of atherogenic dyslipidemia.
    Okopień B; Buldak L; Bołdys A
    Expert Rev Cardiovasc Ther; 2017 Dec; 15(12):913-921. PubMed ID: 29183206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction.
    Tenenbaum A; Fisman EZ
    Cardiovasc Diabetol; 2012 Oct; 11():125. PubMed ID: 23057687
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Benefits and risks of the treatment with fibrates--a comprehensive summary.
    Okopień B; Bułdak Ł; Bołdys A
    Expert Rev Clin Pharmacol; 2018 Nov; 11(11):1099-1112. PubMed ID: 30328735
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: a meta-analysis.
    Lee M; Saver JL; Towfighi A; Chow J; Ovbiagele B
    Atherosclerosis; 2011 Aug; 217(2):492-8. PubMed ID: 21592479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of fibrate treatment in dyslipidemia: an overview.
    Katsiki N; Nikolic D; Montalto G; Banach M; Mikhailidis DP; Rizzo M
    Curr Pharm Des; 2013; 19(17):3124-31. PubMed ID: 23317397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Fibrates in the light of large clinical trials].
    Krysiak R; Rudzki H; Handzlik-Orlik G; Gdula-Dymek A; Okopień B
    Pol Merkur Lekarski; 2015 Apr; 38(226):222-7. PubMed ID: 25938391
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention?
    Tenenbaum A; Fisman EZ
    Cardiovasc Diabetol; 2012 Nov; 11():140. PubMed ID: 23150952
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal pharmacotherapy to combat the atherogenic lipid triad.
    Chapman MJ; Redfern JS; McGovern ME; Giral P
    Curr Opin Cardiol; 2011 Sep; 26(5):403-11. PubMed ID: 21730827
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fibrates effect on cardiovascular risk is greater in patients with high triglyceride levels or atherogenic dyslipidemia profile: a systematic review and meta-analysis.
    Bruckert E; Labreuche J; Deplanque D; Touboul PJ; Amarenco P
    J Cardiovasc Pharmacol; 2011 Feb; 57(2):267-72. PubMed ID: 21052016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Fibrates therapy: Rational use fenofibrate 2016. Executive summary].
    Brea A; Millán J; Ascaso JF; Blasco M; Díaz A; González-Santos P; Hernández-Mijares A; Mantilla T; Pedro-Botet JC; Pintó X;
    Clin Investig Arterioscler; 2016; 28(6):295-301. PubMed ID: 27609708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The combinations of statins and fibrates: pharmacokinetic and clinical implications].
    González Santos P
    Clin Investig Arterioscler; 2014 Jul; 26 Suppl 1():7-11. PubMed ID: 25043540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of dyslipidemias with fibrates, alone and in combination with statins: role of delayed-release fenofibric acid.
    Moutzouri E; Kei A; Elisaf MS; Milionis HJ
    Vasc Health Risk Manag; 2010 Aug; 6():525-39. PubMed ID: 20730069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Place of fibrates for the treatment of patients with atherogenic dyslipidemia].
    Ducobu J; Scheen AJ; Legat P; De Backer G; Van Gaal L; Velkeniers B; Kartounian J; Maes M; Hermans M
    Rev Med Liege; 2009 Oct; 64(10):512-8. PubMed ID: 19911665
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combining a statin with a fibrate versus fibrate monotherapy: efficacious but safe?
    Milionis H
    Expert Opin Drug Saf; 2014 Mar; 13(3):267-9. PubMed ID: 24512564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk.
    Chapman MJ; Redfern JS; McGovern ME; Giral P
    Pharmacol Ther; 2010 Jun; 126(3):314-45. PubMed ID: 20153365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CODAP: A multidisciplinary consensus among Portuguese experts on the definition, detection and management of atherogenic dyslipidemia.
    Mello E Silva A; Aguiar C; Sequeira Duarte J; Couto L; Teixeira Veríssimo M; Marques da Silva P
    Rev Port Cardiol (Engl Ed); 2019 Aug; 38(8):531-542. PubMed ID: 31447268
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PPAR-α agonists are still on the rise: an update on clinical and experimental findings.
    Ferri N; Corsini A; Sirtori C; Ruscica M
    Expert Opin Investig Drugs; 2017 May; 26(5):593-602. PubMed ID: 28343425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Therapeutic targets in the treatment of dyslipidemia: HDL and non-HDL cholesterol].
    Brea Hernando ÁJ
    Clin Investig Arterioscler; 2014 Jul; 26 Suppl 1():3-6. PubMed ID: 25043539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Gastroenterological aspects of atherosclerosis].
    Zvenigorodskaia LA; Samsonova NG; Efremov LI; Cherkashova EA; Lazebnik LB
    Eksp Klin Gastroenterol; 2011; (2):31-6. PubMed ID: 21560640
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Do persons with diabetes benefit from combination statin and fibrate therapy?
    Rosenblit PD
    Curr Cardiol Rep; 2012 Feb; 14(1):112-24. PubMed ID: 22213157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.